Advertisement

Topics

Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU in Older Adults

2018-02-22 19:05:23 | BioPortfolio

Published on BioPortfolio: 2018-02-22T19:05:23-0500

Clinical Trials [1552 Associated Clinical Trials listed on BioPortfolio]

Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU

The main purpose of the this study is to evaluate the safety and tolerability of Immunose™ FLU based on Endocine™ and quadrivalent influenza antigen.

Safety and Immunogencity of H7N9 Influenza Antigen With 2 Adjuvant Formulations in Healthy Adults in Brazil

The overall aim of this study is to evaluate the safety, immunogenicity and dose sparing effects of H7N9 influenza antigen formulated with 2 different adjuvants .

Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older

To evaluate the antibody response to each influenza vaccine antigen when administering a single dose to subjects aged 18 years and over

Immunogenicity of a Surface Antigen, Inactivated Influenza Vaccine Formulation 2007-2008

Due to antigenic changes of influenza viruses, the virus strains used in influenza vaccines are adjusted every year according to WHO and CPMP recommendations. Immunogenicity and tolerabili...

Safety and Immunogenicity of a Commercailly Available Influenza Vaccine (Formulation 2007/2008) When Administered to Elderly Subjects

To evaluate the antibody response to each influenza vaccine antigen when administering a single dose to subjects aged 65 years and over

PubMed Articles [3287 Associated PubMed Articles listed on BioPortfolio]

Monophosphoryl lipid A-adjuvanted virosomes with Ni-chelating lipids for attachment of conserved viral proteins as cross-protective influenza vaccine.

Induction of CD8+ cytotoxic T cells (CTLs) to conserved internal influenza antigens, such as nucleoprotein (NP), is a promising strategy for the development of cross-protective influenza vaccines. How...

Universal influenza virus vaccines and therapeutics: where do we stand with influenza B virus?

The development of a broadly protective or universal influenza virus vaccine is currently a public health priority worldwide. The vast majority of these efforts is exclusively focused on influenza A v...

Estimating burden of influenza-associated influenza-like illness and severe acute respiratory infection at public health care facilities in Romania during the 2011/12-2015/16 influenza seasons.

Influenza is responsible for substantial morbidity and mortality, but there is limited information on reliable disease burden estimates, especially from middle-income countries in the WHO European Reg...

Protective effect of maternal influenza vaccination on influenza in their infants: a prospective cohort study.

Infants under 6 months of age are too young to receive influenza vaccine, despite being at high risk for severe influenza-related complications.

Cell culture-derived flu vaccine: Present and future.

The benefit of influenza vaccines is difficult to estimate due to the complexity of accurately assessing the burden of influenza. To improve the efficacy of influenza vaccines, vaccine manufacturers h...

Medical and Biotech [MESH] Definitions

Species of the genus INFLUENZAVIRUS B that cause HUMAN INFLUENZA and other diseases primarily in humans. Antigenic variation is less extensive than in type A viruses (INFLUENZA A VIRUS) and consequently there is no basis for distinct subtypes or variants. Epidemics are less likely than with INFLUENZA A VIRUS and there have been no pandemics. Previously only found in humans, Influenza B virus has been isolated from seals which may constitute the animal reservoir from which humans are exposed.

Membrane glycoproteins from influenza viruses which are involved in hemagglutination, virus attachment, and envelope fusion. Fourteen distinct subtypes of HA glycoproteins and nine of NA glycoproteins have been identified from INFLUENZA A VIRUS; no subtypes have been identified for Influenza B or Influenza C viruses.

Infection of domestic and wild fowl and other BIRDS with INFLUENZA A VIRUS. Avian influenza usually does not sicken birds, but can be highly pathogenic and fatal in domestic POULTRY.

Human histocompatibility (HLA) surface antigen encoded by the A locus on chromosome 6. The HLA-A2 antigen is associated with recognition of the INFLUENZA A VIRUS.

A genus of the family ORTHOMYXOVIRIDAE comprising viruses similar to types A and B but less common, more stable, more homogeneous, and lacking the neuraminidase protein. They have not been associated with epidemics but may cause mild influenza. Influenza C virus is the type species.

More From BioPortfolio on "Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU in Older Adults"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial